Safety, tolerability and preliminary efficacy results of ORB-CEL-M - a novel mesenchymal stromal cell therapy - in diabetic kidney disease: The multicenter, randomized, placebo-controlled, phase-1b/2a NEPHSTROM clinical trial

被引：0
|
作者：
Remuzzi, G.
Griffin, M.
Cockwell, P.
Maxwell, P.
Perico, N.
Ruggenenti, P.
Introna, M.
Finnerty, A.
Smythe, J.
Fibbe, W.
Elliman, S.
O'Brien, T.
机构：
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2024年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OC10
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 43 条
  • [1] Safety and Preliminary Efficacy Results of a Novel Mesenchymal Stromal Cell Therapy in Diabetic Kidney Disease: The Multicenter, Randomized, Placebo-Controlled, Phase-1b/2a NEPHSTROM Clinical Trial
    Griffin, Matthew D.
    Remuzzi, Giuseppe
    Cockwell, Paul
    Maxwell, Alexander P.
    Perico, Norberto
    Ruggenenti, Piero L.
    Introna, Martino
    Finnerty, Andrew A.
    Smythe, Jon
    Fibbe, Willem E.
    Elliman, Stephen J.
    O'Brien, Timothy
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 29 - 29
  • [2] Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)
    Perico, Norberto
    Remuzzi, Giuseppe
    Griffin, Matthew D.
    Cockwell, Paul
    Maxwell, Alexander P.
    Casiraghi, Federica
    Rubis, Nadia
    Peracchi, Tobia
    Villa, Alessandro
    Todeschini, Marta
    Carrara, Fabiola
    Magee, Bernadette A.
    Ruggenenti, Piero L.
    Rota, Stefano
    Cappelletti, Laura
    Mcinerney, Veronica
    Griffin, Tomas P.
    Islam, Md Nahidul
    Introna, Martino
    Pedrini, Olga
    Golay, Josee
    Finnerty, Andrew A.
    Smythe, Jon
    Fibbe, Willem E.
    Elliman, Stephen J.
    O'Brien, Timothy
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 34 (10): : 1733 - 1751
  • [3] INTERIM REPORT FROM THE NEPHSTROM MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE-1B CLINICAL TRIAL OF A NOVEL MESENCHYMAL STROMAL CELL THERAPY IN PROGRESSIVE DIABETIC KIDNEY DISEASE
    Griffin, M.
    Perico, N.
    Cockwell, P.
    Maxwell, P.
    Rubis, N.
    Casiraghi, F.
    Villa, A.
    Ruggenenti, P.
    Cappelletti, L.
    McInerney, V.
    Duffy, A.
    Finnerty, A.
    Smythe, J.
    Pedrini, O.
    Golay, J.
    Introna, M.
    Steeneveld, E.
    Roelofs, H.
    Fibbe, W.
    Elliman, S. J.
    Remuzzi, G.
    O'Brien, T.
    CYTOTHERAPY, 2022, 24 (05) : S50 - S51
  • [4] Safety and Efficacy ATYR1923, a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial
    Sporn, P. H.
    Culver, D. A.
    Barney, J.
    Maier, L. A.
    James, W. E.
    Hsia, C. C. W.
    Sweiss, N. J.
    Aryal, S.
    Obi, O. N.
    Tabassomi, M.
    Marts, L. T.
    Walker, G.
    Carey, L.
    Shukla, S.
    Baughman, R. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [5] Efficacy and Safety of Tangshen Formula on Patients with Type 2 Diabetic Kidney Disease: A Multicenter Double-Blinded Randomized Placebo-Controlled Trial
    Li, Ping
    Chen, Yiping
    Liu, Jianping
    Hong, Jing
    Deng, Yueyi
    Yang, Fang
    Jin, Xiuping
    Gao, Jing
    Li, Jing
    Fang, Hui
    Liu, Geling
    Shi, Liping
    Du, Jinhang
    Li, Yang
    Yan, Meihua
    Wen, Yumin
    Yang, Wenying
    PLOS ONE, 2015, 10 (05):
  • [6] Efficacy and Safety of Topical WBI-1001 in the Treatment of Atopic Dermatitis: Results From a Phase 2A, Randomized, Placebo-Controlled Clinical Trial
    Bissonnette, Robert
    Chen, Genhui
    Bolduc, Chantal
    Maari, Catherine
    Lyle, Michael
    Tang, Liren
    Webster, John
    Zhou, Youwen
    ARCHIVES OF DERMATOLOGY, 2010, 146 (04) : 446 - 449
  • [7] EFFICACY, SAFETY, AND TOLERABILITY OF IPRAGLIFLOZIN IN ASIAN TYPE 2 DIABETIC PATIENTS WITH INADEQUATE GLYCEMIC CONTROL WITH METFORMIN. RESULTS OF A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL
    Chuang, L. -M.
    Min, K. W.
    Lu, C. -H.
    Kokubo, S.
    Yoshida, S.
    Cha, B. S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S4 - S4
  • [8] Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial
    D'Haens, Geert R.
    Panaccione, Remo
    Higgins, Peter
    Colombel, Jean-Frederic
    Feagan, Brian G.
    Moscariello, Michele
    Chan, Gary
    Healey, Paul J.
    Niezychowski, Wojciech
    Wang, Wenjin
    Marren, Amy
    Maller, Eric
    GASTROENTEROLOGY, 2016, 150 (04) : S183 - S183
  • [9] Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial
    Mkrtumyan, Ashot
    Romantsova, Tatyana
    Vorobiev, Sergei
    Volkova, Anna
    Vorokhobina, Natalia
    Tarasov, Sergey
    Putilovskiy, Mikhail
    Andrianova, Elena
    Epstein, Oleg
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 142 : 1 - 9
  • [10] Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial
    Harris, Violaine K.
    Stark, James
    Williams, Armistead
    Roche, Morgan
    Malin, Michaela
    Kumar, Anjali
    Carlson, Alyssa L.
    Kizilbash, Cara
    Wollowitz, Jaina
    Andy, Caroline
    Gerber, Linda M.
    Sadiq, Saud A.
    STEM CELL RESEARCH & THERAPY, 2024, 15 (01)
12345